US2009192202A1PendingUtilityA1

Androgen modulators

Assignee: PFIZERPriority: Apr 13, 2004Filed: Feb 9, 2009Published: Jul 30, 2009
Est. expiryApr 13, 2024(expired)· nominal 20-yr term from priority
A61P 5/28A61P 35/00A61P 43/00A61P 7/06C07D 213/40C07D 285/01C07D 307/52A61P 13/08C07D 311/76C07D 317/58C07D 471/04A61P 17/10C07D 333/20C07C 255/54A61P 15/00C07D 307/81A61P 17/14C07C 323/41A61P 19/10C07C 2602/08A61P 17/00C07D 209/16C07C 2601/02
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to a new class of 4-cyano-phenoxy-alkyl carboxyl derivatives and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.

Claims

exact text as granted — not AI-modified
1 . A compound of the formula: 
       
         
           
           
               
               
           
         
         in which; 
         a) X 1  is represented by cyano, halogen or haloalkyl, 
         b) R 1  and R 2  are each independently represented by hydrogen or (C 1 -C 6 ) alkyl, optionally substituted, 
         c) Alk 1  is represented by a C 1 -C 2  linear alkylene group, in which up to two hydrogen atoms are optionally replaced by a substituent selected from the group consisting of C 1 -C 6  alkyl optionally substituted, halogen, hydroxy, thiol, and cyano, 
         d) n is represented by the integer 0 or 1, 
         e) Y is represented by NX 2 X 3  or O—X 3 , 
         f) X 2  is represented by hydrogen or (C 1 -C 6 ) alkyl optionally substituted, 
         g) X 3  is represented by
 i. hydrogen, 
 ii. (C 1 -C 12 )alkyl, optionally substituted, 
 iii. (C 2 -C 12 )alkenyl, optionally substituted, 
 iv. (C 2 -C 12 )alkynyl, optionally substituted, 
 v. (C 3 -C 10 )cycloalkyl, optionally substituted, 
 vi. (C 3 -C 10 ) cycloalkyl(C 1 -C 6 )alkyl, in which the alkyl and cycloalkyl moieties may each be optionally substituted, 
 vii. (C 6 -C 10 )aryl, optionally substituted, 
 viii. (C 6 -C 10 )aryl(C 1 -C 6 )alkyl, in which the alkyl and aryl moieties may each be optionally substituted, 
 ix. —(CH 2 )-(Alk 2 ) q -C(O)R 3 , in which Alk 2  is represented by a (C 1 -C 8 ) linear alkylene group, in which up to eight hydrogen atoms may optionally be replaced by a substituent, selected from the group consisting of (C 1 -C 6 ) alkyl optionally substituted, (C 1 -C 6 ) alkoxy, halogen, hydroxy, thiol, cyano, and NR 8 R 9  in which R 8  and R 9  are each independently represented by hydrogen or (C 1 -C 6 ) alkyl, q is the integer 0 or 1, R 3  is represented by hydrogen, (C 1 -C 12 )alkyl, (C 6 -C 10 )aryl, or (C 6 -C 10 )aryl(C 1 -C 6 )alkyl, in which the alkyl and aryl moieties may each be optionally substituted, 
 x. —(CH 2 )-(Alk 2 ) q -C(O)—O—R 4 , in which Alk 2  and q, are as defined above, and R 4  is represented by hydrogen, (C 1 -C 12 )alkyl, (C 6 -C 10 )aryl, or (C 6 -C 10 )aryl(C 1 -C 6 )alkyl, in which the alkyl and aryl moieties may be optionally substituted, 
 xi. —(CH 2 )-(Alk 2 ) q -C(O)—NR 5 R 6  in which Alk 2  and q are as described above, and R 5  and R 6  are each independently represented by hydrogen, (C 1 -C 12 )alkyl, (C 6 -C 10 )aryl, or (C 6 -C 10 )aryl(C 1 -C 6 )alkyl, in which the alkyl and aryl moieties may be optionally substituted, 
 xii. —(CH 2 )-(Alk 2 ) q -Y—R 7 , in which Alk 2  and q are as defined above, Y is O or S, and R 7  is selected from the group consisting of hydrogen, (C 1 -C 12 )alkyl, (C 6 -C 10 )aryl, or (C 6 -C 10 )aryl(C 1 -C 6 )alkyl, in which the alkyl and aryl moieties may be optionally substituted, 
 xiii. heteroaryl, optionally substituted, 
 xiv. heteroaryl(C 1 -C 6 )alkyl, in which the heteroaryl and alkyl moieties may each be optionally substituted, 
 xv. heterocyclic, optionally substituted, 
 xvi. heterocyclic(C 1 -C 6 )alkyl, in which the alkyl
 and heterocyclic moieties may each be substituted, or, 
 
 
         h) for those compounds in which Y is N, X 2  and X 3 , along with the adjacent nitrogen atom, may form a heterocyclic ring, which may optionally be substituted, or a salt, solvate, or prodrug thereof. 
       
     
     
         2 . A compound according to  claim 1  in which one of R 1  or R 2  is hydrogen and the other of R 1  or R 2  is selected from the group consisting of isobutyl, propyl, n-butyl, isopropyl, and ethyl. 
     
     
         3 . A compound according to  claim 1  or  2  in which n is 0. 
     
     
         4 . A compound according to  claim 1 ,  2 , or  3  in which X 1  is trifluoromethyl and is located at the 3-position of the phenyl ring. 
     
     
         5 . A compound according to  claim 1 ,  2 ,  3 , or  4  in which Y is NX 2 X 3 . 
     
     
         6 . A compound according to  claim 5  in which X 2  is hydrogen. 
     
     
         7 . A compound according to  claim 6  in which X 3  is represented by a substituent selected from the group consisting of (C 1 -C 12 )alkyl, (C 3 -C 10 )cycloalkyl(C 1 -C 6 )alkyl, (C 6 -C 10 )aryl(C 1 -C 6 alkyl, heteroaryl(C 1 -C 6 )alkyl, and heterocyclic(C 1 -C 6 )alkyl. 
     
     
         8 . A compound according to  claim 1 ,  2 ,  3 , or  4  in which Y is OX 3 . 
     
     
         9 . A compound according to anyone of  claims 1 - 8  in which X 1  is represented by halogen or haloalkyl. 
     
     
         10 . Use of a compound according to anyone of  claims 1 - 9  as a medicine. 
     
     
         11 . Use of a compound according to anyone of  claims 1 - 9  in the manufacture of a medicament for inhibiting activation of the androgen receptor 
     
     
         12 . Use of a compound according to anyone of  claims 1 - 9  in the manufacture of a medicament for the alleviating a condition selected from the group consisting of hormone dependent cancers, benign hyperplasia of the prostate, acne, hirsutism, excess sebum, alopecia, premenstrual syndrome, lung cancer, precocious puberty, osteoporosis, hypogonadism, age-related decrease in muscle mass, and anemia. 
     
     
         13 . A pharmaceutical composition comprising a compound according to anyone of  claims 1 - 9  in admixture with 1, or more, pharmaceutically acceptable excipients. 
     
     
         14 . A topical pharmaceutical formulation comprising a compound according to anyone of  claims 1 - 9  in admixture with 1, or more, pharmaceutically acceptable excipients suitable for dermal application. 
     
     
         15 . An article of manufacture comprising a compound according to anyone of  claims 1 - 9  packaged for retail distribution, which advises a consumer how to utilize the compound to alleviate a condition selected from the group consisting of acne, alopecia, and oily skin.

Join the waitlist — get patent alerts

Track US2009192202A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.